Journal of Genetic Medicine

  • 제17권2호
  • /
  • Pages.55-61
  • /
  • 2020
  • /
  • 1226-1769(pISSN)
  • /
  • 2383-8442(eISSN)
대한의학유전학회 (Korean Society of Medical Genetics and Genomics)
권호 표지
DOI QR코드

DOI QR Code

Rehabilitation of spinal muscular atrophy: current consensus and future direction

  • Yi, You Gyoung (Department of Rehabilitation Medicine, National Traffic Injury Rehabilitation Hospital) ;
  • Shin, Hyung-Ik (Department of Rehabilitation, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Jang, Dae-Hyun (Department of Rehabilitation, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • 투고 : 2020.11.25
  • 심사 : 2020.12.03
  • 발행 : 2020.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Spinal muscular atrophy (SMA) is a neuromuscular disease that requires multidisciplinary medical care, including rehabilitation management. The emergence of a genetic therapy-based approach for SMA has markedly changed the disease course. Nonetheless, currently, updated physical therapy and rehabilitation are warranted for individuals with SMA in the era of gene therapy. In this review, we discuss the physical therapy and rehabilitation strategies currently performed for people with SMA, such as positioning and bracing, supported standing, management of musculoskeletal deformities, stretching, physical exercise training like aerobics and strengthening exercises, assistive devices, pulmonary rehabilitation, and dysphagia treatment.

키워드

참고문헌

  1. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al.; SMA Care Group. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord 2018;28:103-15. https://doi.org/10.1016/j.nmd.2017.11.005
  2. Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al.; CHERISH Study Group. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med 2018;378:625-35. https://doi.org/10.1056/NEJMoa1710504
  3. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-65. https://doi.org/10.1016/0092-8674(95)90460-3
  4. Czech C, Tang W, Bugawan T, Mano C, Horn C, Iglesias VA, et al. Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls. PLoS One 2015;10:e0139950. https://doi.org/10.1371/journal.pone.0139950
  5. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al.; NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 2017;82:883-91. https://doi.org/10.1002/ana.25101
  6. Rudnik-Schoneborn S, Hausmanowa-Petrusewicz I, Borkowska J, Zerres K. The predictive value of achieved motor milestones assessed in 441 patients with infantile spinal muscular atrophy types II and III. Eur Neurol 2001;45:174-81. https://doi.org/10.1159/000052118
  7. Castro D, Iannaccone ST. Spinal muscular atrophy: therapeutic strategies. Curr Treat Options Neurol 2014;16:316. https://doi.org/10.1007/s11940-014-0316-3
  8. Rathore FA, Afridi A. Does physical exercise training improve functional performance in type 3 spinal muscular atrophy? A Cochrane Review summary with commentary. Dev Med Child Neurol 2020;62:1014-6. https://doi.org/10.1111/dmcn.14622
  9. Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, et al.; Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007;22:1027-49. https://doi.org/10.1177/0883073807305788
  10. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al.; ENDEAR Study Group. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017;377:1723-32. https://doi.org/10.1056/NEJMoa1702752
  11. Hully M, Barnerias C, Chabalier D, Le Guen S, Germa V, Deladriere E, et al. Palliative care in SMA type 1: a prospective multicenter French study based on parents' reports. Front Pediatr 2020;8:4. https://doi.org/10.3389/fped.2020.00004
  12. Montes J, Dunaway Young S, Mazzone ES, Pasternak A, Glanzman AM, Finkel RS, et al.; CS2 and CS12 Study Groups. Nusinersen improves walking distance and reduces fatigue in later-onset spinal muscular atrophy. Muscle Nerve 2019;60:409-14. https://doi.org/10.1002/mus.26633
  13. Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry 2020;91:1166-74. https://doi.org/10.1136/jnnp-2020-323822
  14. Lavie M, Diamant N, Cahal M, Sadot E, Be'er M, Fattal-Valevski A, et al. Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience. Pediatr Pulmonol 2021;56:291-8. https://doi.org/10.1002/ppul.25140
  15. Gomez-Garcia de la Banda M, Amaddeo A, Khirani S, Pruvost S, Barnerias C, Dabaj I, et al. Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen. Pediatr Pulmonol 2021;56:299-306. https://doi.org/10.1002/ppul.25142
  16. Trucco F, Ridout D, Scoto M, Coratti G, Main ML, Lofra RM, et al.; international SMA consortium (iSMAc). Respiratory trajectories in type 2 and non-ambulant 3 Spinal muscular atrophy in the iSMAC cohort study. Neurology 2020, in press.
  17. Stevens D, Claborn MK, Gildon BL, Kessler TL, Walker C. Onasemnogene abeparvovec-xioi: gene therapy for spinal muscular atrophy. Ann Pharmacother 2020;54:1001-9. https://doi.org/10.1177/1060028020914274
  18. Waldrop MA, Karingada C, Storey MA, Powers B, Iammarino MA, Miller NF, et al. Gene therapy for spinal muscular atrophy: safety and early outcomes. Pediatrics 2020;146:e20200729. https://doi.org/10.1542/peds.2020-0729
  19. Vu-Han TL, Weiss C, Pumberger M. Novel therapies for spinal muscular atrophy are likely changing the patient phenotype. Spine J 2020;20:1893-8. https://doi.org/10.1016/j.spinee.2020.08.013
  20. Brown JE, Thompson M, Brizzolara K. Head control changes after headpod use in children with poor head control: a feasibility study. Pediatr Phys Ther 2018;30:142-8. https://doi.org/10.1097/PEP.0000000000000492
  21. Garg S. Management of scoliosis in patients with Duchenne muscular dystrophy and spinal muscular atrophy: a literature review. J Pediatr Rehabil Med 2016;9:23-9. https://doi.org/10.3233/PRM-160358
  22. Townsend EL, Simeone SD, Krosschell KJ, Zhang RZ, Swoboda KJ; Project Cure SMA Investigator's Network. Stander use in spinal muscular atrophy: results from a large natural history database. Pediatr Phys Ther 2020;32:235-41. https://doi.org/10.1097/PEP.0000000000000713
  23. Sumner CJ, Fischbeck KH. Spinal muscular atrophy. In: Gilman S, ed. Neurobiology of disease. Cambridge: Academic Press, 2007;501-11.
  24. Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol 2012;11:443-52. https://doi.org/10.1016/S1474-4422(12)70061-3
  25. Stepien A, Mazurkiewicz L, Maslanko K, Rekowski W, Jedrzejowska M. Cervical rotation, chest deformity and pelvic obliquity in patients with spinal muscular atrophy. BMC Musculoskelet Disord 2020;21:726. https://doi.org/10.1186/s12891-020-03710-7
  26. Sporer SM, Smith BG. Hip dislocation in patients with spinal muscular atrophy. J Pediatr Orthop 2003;23:10-4. https://doi.org/10.1097/01241398-200301000-00002
  27. Montes J, Young SD, Mazzone E, Main M. First international workshop on rehabilitation management and clinical outcome measures for spinal muscular atrophy. Neuromuscul Disord 2017;27:964-9. https://doi.org/10.1016/j.nmd.2017.07.005
  28. Sheikh AM, Vissing J. Exercise therapy for muscle and lower motor neuron diseases. Acta Myol 2019;38:215-32.
  29. Dunaway S, Montes J, McDermott MP, Martens W, Neisen A, Glanzman AM, et al. Physical therapy services received by individuals with spinal muscular atrophy (SMA). J Pediatr Rehabil Med 2016;9:35-44. https://doi.org/10.3233/PRM-160360
  30. Rahman T, Sample W, Seliktar R, Scavina MT, Clark AL, Moran K, et al. Design and testing of a functional arm orthosis in patients with neuromuscular diseases. IEEE Trans Neural Syst Rehabil Eng 2007;15:244-51. https://doi.org/10.1109/TNSRE.2007.897026
  31. Biondi O, Grondard C, Lecolle S, Deforges S, Pariset C, Lopes P, et al. Exercise-induced activation of NMDA receptor promotes motor unit development and survival in a type 2 spinal muscular atrophy model mouse. J Neurosci 2008;28:953-62. https://doi.org/10.1523/JNEUROSCI.3237-07.2008
  32. Chali F, Desseille C, Houdebine L, Benoit E, Rouquet T, Bariohay B, et al. Long-term exercise-specific neuroprotection in spinal muscular atrophy-like mice. J Physiol 2016;594:1931-52. https://doi.org/10.1113/JP271361
  33. Bartels B, Montes J, van der Pol WL, de Groot JF. Physical exercise training for type 3 spinal muscular atrophy. Cochrane Database Syst Rev 2019;3:CD012120.
  34. Preisler N, Andersen G, Thogersen F, Crone C, Jeppesen TD, Wibrand F, et al. Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology 2009;72:317-23. https://doi.org/10.1212/01.wnl.0000341274.61236.02
  35. Lewelt A, Krosschell KJ, Stoddard GJ, Weng C, Xue M, Marcus RL, et al. Resistance strength training exercise in children with spinal muscular atrophy. Muscle Nerve 2015;52:559-67. https://doi.org/10.1002/mus.24568
  36. Ng SY, Manta A, Ljubicic V. Exercise biology of neuromuscular disorders. Appl Physiol Nutr Metab 2018;43:1194-206. https://doi.org/10.1139/apnm-2018-0229
  37. Montes J, Garber CE, Kramer SS, Montgomery MJ, Dunaway S, Kamil-Rosenberg S, et al. Single-blind, randomized, controlled clinical trial of exercise in ambulatory spinal muscular atrophy: why are the results negative? J Neuromuscul Dis 2015;2:463-70. https://doi.org/10.3233/JND-150101
  38. Madsen KL, Hansen RS, Preisler N, Thogersen F, Berthelsen MP, Vissing J. Training improves oxidative capacity, but not function, in spinal muscular atrophy type III. Muscle Nerve 2015;52:240-4. https://doi.org/10.1002/mus.24527
  39. Bora G, Subasi-Yildiz S, Yesbek-Kaymaz A, Bulut N, Alemdaroglu I, Tunca-Yilmaz O, et al. Effects of arm cycling exercise in spinal muscular atrophy type II patients: a pilot study. J Child Neurol 2018;33:209-15. https://doi.org/10.1177/0883073817750500
  40. Grondard C, Biondi O, Armand AS, Lecolle S, Della Gaspera B, Pariset C, et al. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J Neurosci 2005;25:7615-22. https://doi.org/10.1523/JNEUROSCI.1245-05.2005
  41. Ng SY, Mikhail A, Ljubicic V. Mechanisms of exercise-induced survival motor neuron expression in the skeletal muscle of spinal muscular atrophy-like mice. J Physiol 2019;597:4757-78. https://doi.org/10.1113/jp278454
  42. Heje K, Andersen G, Buch A, Andersen H, Vissing J. High-intensity training in patients with spinal and bulbar muscular atrophy. J Neurol 2019;266:1693-7. https://doi.org/10.1007/s00415-019-09316-x
  43. Essers J, Murgia A, Peters A, Meijer K. Daily life benefits and usage characteristics of dynamic arm supports in subjects with neuromuscular disorders. Sensors (Basel) 2020;20:4864. https://doi.org/10.3390/s20174864
  44. Essers JMN, Murgia A, Peters AA, Janssen MMHP, Meijer K. Recommendations for studies on dynamic arm support devices in people with neuromuscular disorders: a scoping review with expert-based discussion. Disabil Rehabil Assist Technol 2020, in press.
  45. Jones MA, McEwen IR, Hansen L. Use of power mobility for a young child with spinal muscular atrophy. Phys Ther 2003;83:253-62. https://doi.org/10.1093/ptj/83.3.253
  46. Bach JR, Baird JS, Plosky D, Navado J, Weaver B. Spinal muscular atrophy type 1: management and outcomes. Pediatr Pulmonol 2002;34:16-22. https://doi.org/10.1002/ppul.10110
  47. Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 2014;83:810-7. https://doi.org/10.1212/WNL.0000000000000741
  48. Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics 2009;123 Suppl 4:S245-9. https://doi.org/10.1542/peds.2008-2952K
  49. Stehling F, Bouikidis A, Schara U, Mellies U. Mechanical insufflation/exsufflation improves vital capacity in neuromuscular disorders. Chron Respir Dis 2015;12:31-5. https://doi.org/10.1177/1479972314562209
  50. Choi YA, Suh DI, Chae JH, Shin HI. Trajectory of change in the swallowing status in spinal muscular atrophy type I. Int J Pediatr Otorhinolaryngol 2020;130:109818. https://doi.org/10.1016/j.ijporl.2019.109818
  51. Yi YG, Oh BM, Yang S, Shin HI. Oral feeding challenges in children with tracheostomy can improve feeding outcomes, even with the finding of aspiration. Front Pediatr 2019;7:362. https://doi.org/10.3389/fped.2019.00362